US 4,341,870 A · Cultivatable human rotavirus type 2

Cultivatable human rotavirus type 2

AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services

InventorsRichard G. Wyatt, Walter D. James, Edward H. Bohl, Kenneth W. Theil, Linda J. Saif, Anthony R. Kalica, Harry B. Greenberg, Albert Z. Kapikian, Robert M. Chanock

Life of this patent

Estimating the term…

Abstract

This invention relates to a precursor or intermediate for a rotavirus vaccine to protect infants and young children against diarrhea caused by rotavirus. The invention is the efficient propagation of a strain of human rotavirus type 2 prepared by a method of cultivation by multiple passages in vivo in gnotobiotic piglets and by multiple passages in vitro subsequently in AGMK (African green monkey kidney) cell cultures. Additionally, rotavirus is treated with a biologically active amount of trypsin prior to growth in AGMK cells, and the inoculated cell cultures are centrifuged at a low centrifugal force before incubation.

Claims2

Dependent claims

A precursor for a diarrhea vaccine which is a human rotavirus type 2 prepared by a method of cultivation of the Wa strain of human rotavirus type 2 through eleven passages in vivo using gnotobiotic piglets, then taking that virus and passing it through 14 to 25 passages in vitro in African green monkey kidney cell cultures;

and wherein prior to each of said kidney cell cultures the rotavirus is treated with an effective amount of trypsin and where at each passage the tissue culture inoculated with rotavirus is subjected to low force centrifugation.

Dependencies are inferred from the claim text.